SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
-0.73%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$993M
AUM Growth
+$993M
(-6.1%)
Cap. Flow
-$17.6M
Cap. Flow
% of AUM
-1.77%
Top 10 Holdings %
Top 10 Hldgs %
99.96%
Holding
11
New
–
Increased
–
Reduced
4
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
Gilead Sciences
GILD
|
$13.7M |
| 2 |
RGLS
Regulus Therapeutics
RGLS
|
$3.45M |
| 3 |
Vor Biopharma
VOR
|
$442K |
| 4 |
AMRN
Amarin Corp
AMRN
|
$2.98K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alkermes
ALKS
$4.78B
| $418M | 42.1% | 14,040,000 | – | – |
|
2
Ironwood Pharmaceuticals
IRWD
$214M
| $189M | 19.02% | 16,390,000 | – | – |
|
3
Biogen
BIIB
$19.4B
| $131M | 13.2% | 643,000 | – | – |
|
4
Innoviva
INVA
$1.29B
| $97.6M | 9.83% | 6,614,000 | – | – |
|
|
5
Gilead Sciences
GILD
$140B
| $82.9M | 8.35% | 1,341,900 -221,000 | -14% | -$13.7M |
|
|
AMRN
6
Amarin Corp
AMRN
$311M
| $35.8M | 3.6% | 23,998,000 -2,000 | -0% | -$2.98K |
|
7
Mersana Therapeutics
MRSN
$36.5M
| $19.9M | 2% | 4,299,297 | – | – |
|
8
BioCryst Pharmaceuticals
BCRX
$1.74B
| $14.7M | 1.48% | 1,390,790 | – | – |
|
|
9
Vor Biopharma
VOR
$250M
| $3.07M | 0.31% | 618,000 -89,010 | -13% | -$442K |
|
|
PEAR
10
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $771K | 0.08% | 500,356 | – | – |
|
|
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
| $383K | 0.04% | 185,183 -1,666,668 | -90% | -$3.45M |
|